209 results on '"Rocha, José-Francisco"'
Search Results
2. OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2
3. Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
4. Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
5. Opicapone to Treat Early Wearing‐off in Parkinson's Disease Patients: The Korean ADOPTION Trial
6. Biological and physicochemical implications of the aging process on titanium and zirconia implant material surfaces
7. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial
8. Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
9. Opicapone, a Novel Catechol-O-Methyltranferase Inhibitor (COMT) to Manage the Symptoms of Parkinson's Disease
10. Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study
11. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
12. The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
13. Effect of opicapone multiple‐dose regimens on levodopa pharmacokinetics
14. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial
15. 0581 Sleep Patterns and “OFF”-Time in Patients with Parkinson’s Disease and Motor Fluctuations
16. Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study
17. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations
18. Effect of moderate liver impairment on the pharmacokinetics of opicapone
19. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease
20. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects
21. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers
22. The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
23. Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone
24. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study
25. Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects: Prediction of Slow Enzyme–Inhibitor Complex Dissociation of a Short-Living and Very Long-Acting Inhibitor
26. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers
27. Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate: Randomized, Open-Label, Crossover, Single-Centre Study in Healthy Volunteers
28. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
29. Long-term Efficacy of Opicapone in the Reduction of ON-time with Troublesome Dyskinesia in Parkinson’s Disease Patients with Motor Fluctuations and Reporting Troublesome Dyskinesia (1609)
30. Media mix modeling: a case study on optimizing television and digital media spend for a retailer
31. CONHECIMENTO EM GADO DE LEITE: MASTITE
32. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects
33. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers
34. Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5-453), a New Dopamine β-Hydroxylase Inhibitor, in Healthy Subjects
35. Efficacy of Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: a Post-Hoc Analysis from Double-Blind Combined BIPARK-I and II Data (1502)
36. Effectiveness and Safety of Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: the OPTIPARK Study (1150)
37. A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinsonʼs Disease
38. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers
39. Pharmacokinetics of Trans-resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects
40. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers.
41. Effect of the aging process on physical and biological properties of biomaterials used as abutments
42. Safety Profile of Opicapone in the Management of Parkinson’s Disease
43. Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies (S4.003)
44. AN INTEGRATED ASSESSMENT OF PHARMACOKINETICS AND PHARMACODYNAMICS OF ZAMICASTAT: A DOPAMINE Β-HYDROXYLASE INHIBITOR IN HEALTHY VOLUNTEERS
45. Effect of opicapone multiple‐dose regimens on levodopa pharmacokinetics
46. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
47. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease
48. Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much “fair” is “fair”
49. Oxidative stress by Haemonchus contortus in lambs: Influence of treatment with zinc edetate
50. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.